Cellestia Biotech is pioneering innovative therapeutics based on novel modes of action to treat autoimmune diseases and multi-drug resistant cancers. Our clinical stage drug candidate, CB-103, has demonstrated both safety and biological activity in humans. Along with ongoing Phase 2 IITs for multi-drug resistant cancers, CB-103 is also poised to enter a Proof-of-Concept clinical study for graft-versus-host disease (GvHD)
Company Details
- Employees
- 8
- Founded
- 2014
- Address
- Hochbergerstrasse, Basel,basel-Town 4057,switzerland
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.cellestia.com/
- Keywords
- Biopharma, Oncology, Precision Medicine, Small Molecules, Targeted Therapy, Biotech, Cancer Therapy, Transcription Factors, Autoimmune Disorders, Inflammatory Disorders.
- HQ
- Basel, Basel-Town
Cellestia Biotech Questions
Cellestia Biotech's website is https://www.cellestia.com/
Cellestia Biotech's LinkedIn profile is https://ch.linkedin.com/company/cellestia-biotech
Cellestia Biotech has
8 employees.
View email and phone details for 8
employees at Cellestia Biotech.
Cellestia Biotech's industry is
Biotechnology Research
Cellestia Biotech's top competitors are
Tolremo Therapeutics,
Biopôle Lausanne,
Nbe-Therapeutics Ag,
Cutiss Ag,
Alentis Therapeutics,
Limula,
T3 Pharmaceuticals Ag,
Haya Therapeutics,
Araris Biotech Ag,
Anaveon Ag.
Cellestia Biotech's categories are Biotechnology Research
Cellestia Biotech's founding year is 2014
